Ranjita Pallavi, MD
Medical Oncology · Pittsburgh, PANPI 1063760676
Payments from drug & device makers
Across 166 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$282
- Cardinal Health 110 LLC$275
- Amgen$259
- Pfizer$253
- Novartis$246
- Incyte Corporation$208
- plus $2K from 32 others
What the payments were for
- Consulting fees$67518%
- Food & beverage$2,65772%
- Education$35610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $282 |
| Cardinal Health 110 LLC | 1 | $275 |
| Amgen | 15 | $259 |
| Pfizer | 15 | $253 |
| Novartis | 16 | $246 |
| Incyte Corporation | 8 | $208 |
| Sobi, Inc | 1 | $200 |
| Covis Pharma GmbH | 1 | $200 |
| AstraZeneca | 11 | $183 |
| E.r. Squibb & Sons, L.L.C. | 5 | $181 |
| Genentech USA, Inc. | 8 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $132 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $92 |
| EMD Serono, Inc. | 6 | $90 |
| Bristol Myers Squibb | 5 | $88 |
| Eisai Inc. | 4 | $85 |
| Astellas Pharma US Inc | 1 | $78 |
| Bayer | 4 | $75 |
| AbbVie | 4 | $68 |
| Daiichi Sankyo Inc. | 4 | $61 |
| Boehringer Ingelheim | 3 | $49 |
| Seagen Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $45 |
| Blueprint Medicines Corporation | 2 | $45 |
| AMAG Pharmaceuticals, Inc. | 3 | $43 |
| Puma Biotechnology, Inc. | 2 | $38 |
| Acrotech Biopharma Inc. | 1 | $29 |
| Sanofi | 2 | $27 |
| GSK | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Tesaro, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Dova Pharmaceuticals | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,688 in reported general payments places this provider in the 35th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 36 | $559,420 |
| CabometyxCabozantinib S-Malate | 22 | $555,012 |
| CalquenceAcalabrutinib Maleate | 25 | $353,992 |
| ImbruvicaIbrutinib | 18 | $284,353 |
| NubeqaDarolutamide | 33 | $280,542 |
| VenclextaVenetoclax | 27 | $269,419 |
| ErleadaApalutamide | 18 | $243,565 |
| Lenalidomide | 15 | $182,119 |
| IbrancePalbociclib | 13 | $181,174 |
| BrukinsaZanubrutinib | 16 | $113,781 |
| KisqaliRibociclib Succinate | 11 | $82,227 |
| EliquisApixaban | 99 | $63,053 |
| Posaconazole | 14 | $41,968 |
| XareltoRivaroxaban | 24 | $14,678 |
| Abiraterone Acetate | 15 | $7,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $208 | $559,42036 claims |
| AstraZenecaCalquence | $183 | $353,99225 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $92 | $284,35318 claims |
| BayerNubeqa | $75 | $280,54233 claims |
| AbbVieVenclexta | $68 | $269,41927 claims |
| Johnson & JohnsonErleada, Xarelto | $45 | $258,24342 claims |
| PfizerIbrance, Eliquis | $253 | $244,227112 claims |
| NovartisKisqali | $246 | $82,22711 claims |
| Lilly USA, LLCOlanzapine | $12 | $28211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Pittsburgh
- Adam BrufskyPittsburgh$6M
- John KirkwoodPittsburgh$3.4M
- Melissa BurgessPittsburgh$2.4M
- Nathan BaharyPittsburgh$2.1M
- Jane RaymondPittsburgh$794K
- Ariel Lopez-ChavezPittsburgh$727K
- Ashwin SomasundaramPittsburgh$696K
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.